InflaRx (IFRX) Competitors $1.28 +0.03 (+2.40%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$1.30 +0.01 (+1.17%) As of 10/14/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IFRX vs. KMDA, YMAB, DRUG, ETHZ, CGEM, ENGN, AURA, TVRD, EDIT, and AARDShould you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Kamada (KMDA), Y-mAbs Therapeutics (YMAB), Bright Minds Biosciences (DRUG), Flag Ship Acquisition (ETHZ), Cullinan Therapeutics (CGEM), enGene (ENGN), Aura Biosciences (AURA), Tvardi Therapeutics (TVRD), Editas Medicine (EDIT), and Aardvark Therapeutics (AARD). These companies are all part of the "pharmaceutical products" industry. InflaRx vs. Its Competitors Kamada Y-mAbs Therapeutics Bright Minds Biosciences Flag Ship Acquisition Cullinan Therapeutics enGene Aura Biosciences Tvardi Therapeutics Editas Medicine Aardvark Therapeutics InflaRx (NASDAQ:IFRX) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings. Do institutionals & insiders have more ownership in IFRX or KMDA? 42.4% of InflaRx shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 36.1% of Kamada shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer IFRX or KMDA? InflaRx currently has a consensus price target of $6.20, indicating a potential upside of 384.38%. Kamada has a consensus price target of $13.00, indicating a potential upside of 90.62%. Given InflaRx's higher possible upside, equities research analysts clearly believe InflaRx is more favorable than Kamada.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67Kamada 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more risk and volatility, IFRX or KMDA? InflaRx has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Kamada has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Which has better valuation and earnings, IFRX or KMDA? Kamada has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInflaRx$180K477.37-$49.85M-$0.80-1.60Kamada$160.95M2.44$14.46M$0.3420.06 Does the media favor IFRX or KMDA? In the previous week, Kamada had 1 more articles in the media than InflaRx. MarketBeat recorded 4 mentions for Kamada and 3 mentions for InflaRx. InflaRx's average media sentiment score of 0.83 beat Kamada's score of 0.77 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kamada 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is IFRX or KMDA more profitable? Kamada has a net margin of 11.22% compared to InflaRx's net margin of 0.00%. Kamada's return on equity of 7.41% beat InflaRx's return on equity.Company Net Margins Return on Equity Return on Assets InflaRxN/A -71.76% -57.68% Kamada 11.22%7.41%5.18% SummaryKamada beats InflaRx on 10 of the 16 factors compared between the two stocks. Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IFRX vs. The Competition Export to ExcelMetricInflaRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.92M$3.35B$6.04B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-1.6021.9085.1027.24Price / Sales477.37422.17556.60219.52Price / CashN/A46.9537.5761.53Price / Book1.1310.4312.346.74Net Income-$49.85M-$52.58M$3.32B$276.59M7 Day Performance-12.93%-1.55%-1.33%-0.47%1 Month Performance4.07%12.96%8.12%7.47%1 Year Performance-13.51%15.43%73.80%34.58% InflaRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IFRXInflaRx2.3623 of 5 stars$1.28+2.4%$6.20+384.4%-14.7%$83.92M$180K-1.6060News CoverageAnalyst ForecastGap DownKMDAKamada4.4831 of 5 stars$6.93+1.3%$13.00+87.6%+29.4%$393.33M$160.95M20.38360News CoverageYMABY-mAbs Therapeutics1.2885 of 5 stars$8.61flat$9.62+11.8%N/A$391.24M$87.68M-17.22150DRUGBright Minds Biosciences2.6126 of 5 stars$61.41+11.3%$81.00+31.9%+2,645.8%$388.83MN/A-66.03N/APositive NewsGap DownETHZFlag Ship AcquisitionN/A$2.19-5.6%N/AN/A$381.48MN/A-0.157Gap UpCGEMCullinan Therapeutics3.3224 of 5 stars$7.05+9.3%$26.00+268.8%-52.3%$381.03MN/A-2.1830Positive NewsHigh Trading VolumeENGNenGene2.7482 of 5 stars$8.89+20.0%$19.50+119.3%+14.1%$379.33MN/A-4.6831Trending NewsAnalyst ForecastGap UpHigh Trading VolumeAURAAura Biosciences1.9757 of 5 stars$6.03-1.0%$22.00+264.8%-34.0%$378.31MN/A-3.0850TVRDTvardi Therapeutics2.8877 of 5 stars$42.98+7.7%$64.25+49.5%N/A$374.25M$7.14M0.0080Trending NewsAnalyst DowngradeEDITEditas Medicine4.2833 of 5 stars$4.08-1.7%$5.10+25.0%+10.8%$373.17M$38.90M-1.43230Gap DownAARDAardvark Therapeutics4.4641 of 5 stars$16.59-3.2%$31.43+89.4%N/A$371.67MN/A0.0018 Related Companies and Tools Related Companies Kamada Competitors Y-mAbs Therapeutics Competitors Bright Minds Biosciences Competitors Flag Ship Acquisition Competitors Cullinan Therapeutics Competitors enGene Competitors Aura Biosciences Competitors Tvardi Therapeutics Competitors Editas Medicine Competitors Aardvark Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IFRX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
